EurekAlert! -
20 Jan 2021 07:00
(University of California - San Diego) UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma.
Share this Article